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a mathematical modelling study
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Abstract
Background: Antibiotic resistance is threatening to make gonorrhoea untreatable. Point-of-care (POC) tests that
detect resistance promise individually tailored treatment, but might lead to more treatment and higher levels of
resistance. We investigate the impact of POC tests on antibiotic-resistant gonorrhoea.
Methods: We used data about the prevalence and incidence of gonorrhoea in men who have sex with men (MSM)
and heterosexual men and women (HMW) to calibrate a mathematical gonorrhoea transmission model. With this
model, we simulated four clinical pathways for the diagnosis and treatment of gonorrhoea: POC test with (POC + R)
and without (POC − R) resistance detection, culture and nucleic acid amplification tests (NAATs). We calculated the
proportion of resistant infections and cases averted after 5 years, and compared how fast resistant infections spread in
the populations.
Results: The proportion of resistant infections after 30 years is lowest for POC+ R (median MSM: 0.18%, HMW: 0.12%),
and increases for culture (MSM: 1.19%, HMW: 0.13%), NAAT (MSM: 100%, HMW: 99.27%), and POC − R (MSM: 100%,
HMW: 99.73%). Per 100 000 persons, NAAT leads to 36 366 (median MSM) and 1228 (median HMW) observed cases
after 5 years. Compared with NAAT, POC+ R averts more cases after 5 years (median MSM: 3353, HMW: 118). POC tests
that detect resistance with intermediate sensitivity slow down resistance spread more than NAAT. POC tests with very
high sensitivity for the detection of resistance are needed to slow down resistance spread more than by using culture.
Conclusions: POC with high sensitivity to detect antibiotic resistance can keep gonorrhoea treatable longer than
culture or NAAT. POC tests without reliable resistance detection should not be introduced because they can
accelerate the spread of antibiotic-resistant gonorrhoea.
Keywords: Gonorrhoea, Bacterial drug resistance, Point-of-care testing, Mathematical model, Sexually transmitted
infection, Epidemiology
Background
Antibiotic resistance is a major challenge for the man-
agement of gonorrhoea globally: extended-spectrum
cephalosporins are the last antibiotic class remaining for
empirical treatment of gonorrhoea [1, 2], and 42 countries
have already reported Neisseria gonorrhoeae strains with
decreased susceptibility against them [2]. The first strain
with high-level resistance to the recommended combi-
nation therapy with ceftriaxone and azithromycin was
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recently described [3]. With an estimated 78 million new
gonorrhoea cases each year [4], new control strategies are
urgently needed before gonorrhoea becomes untreatable.
Conventional diagnostic tests for gonorrhoea, such as
nucleic acid amplification tests (NAATs) and culture,
are not sufficient to control antibiotic resistance. Com-
mercially available NAATs, the most commonly used
diagnostic gonorrhoea tests in high-income countries,
cannot detect antibiotic resistance [5, 6]. Cultures of
N. gonorrhoeae can be used to determine antibiotic-
resistance profiles, but reliable results depend on stringent
collection and transport of specimens [7]. Culture and
susceptibility testing need several days to deliver results
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[8]. NAATs can deliver results in a few hours [9], but in
routine use specimens might be tested in batches [10]
and NAAT results might be delivered only after several
days [11].While symptomatic gonorrhoea patients usually
receive empirical treatment at their first visit, asymp-
tomatic patients might have to return for treatment. Loss
to follow-up and the further spread of resistant infections
can result.
Point-of-care (POC) tests promise to help control
antibiotic resistance [12]. POC tests provide results
rapidly and allow informed clinical decisions about treat-
ment at the first visit of a patient. POC tests, there-
fore, reduce the time to treatment and avoid loss to
follow-up. A modelling study suggested that POC tests
can reduce gonorrhoea prevalence if no antibiotic resis-
tance is present in the population [13]. Though not
yet commercially available [12], POC tests that detect
resistance promise to reduce the use of antibiotics [14]
and to spare last-line antibiotics through individually
tailored treatment [15, 16]. One modelling study illus-
trated that individualised treatment could slow down the
spread of resistance as much as combination therapy
[17]. However, reduced time to treatment and increased
follow-up with POC tests might increase the rate of
gonorrhoea treatment. Since higher treatment rates can
lead to the faster spread of resistance [18, 19], POC
tests might increase resistance levels. We extended a
previously developed mathematical model of gonor-
rhoea transmission [19] to compare the effects of cur-
rent conventional tests (culture and NAATs) with POC
tests that reduce time to treatment and loss to follow-
up. We investigated the potential impact of POC tests
on resistance and on the number of gonorrhoea cases
for a population at high risk of infection [20], men
who have sex with men (MSM), and a population at
lower risk of infection, heterosexual men and women
(HMW).
Methods
We developed a mathematical model that describes trans-
mission of antibiotic-sensitive and -resistant gonorrhoea,
clinical pathways for diagnostic testing with culture,
NAAT, or POC, and treatment with first- and second-
line antibiotics (Additional file 1: SectionModel). Here we
describe the model, focusing on testing and treatment of
gonorrhoea (Fig. 1 and Table 1).
Basic model structure
The model is based on our previously published compart-
mental model of gonorrhoea transmission and resistance
spread [19]. The model describes a population with two
sexual activity classes i ∈ C, where C = {L,H} indi-
cates that there are two sexual activity classes L and
H with low and high partner change rates. The model
incorporates sexual mixing between the sexual activity
classes, sexual behaviour change, migration in and out
of the population, and gonorrhoea transmission. Indi-
viduals in the population can be susceptible to infec-
tion, Si, infected with antibiotic-sensitive gonorrhoea,
ISeni , infected with gonorrhoea resistant to the first-line
antibiotic, IResi , or infected with gonorrhoea resistant to
the first-line antibiotic and waiting for re-treatment, Wi.
Depending on the parameters for sexual behaviour, trans-
mission, and gonorrhoea natural history (Additional file 1:
Table S2), the model describes a population of MSM
or HMW.
Gonorrhoea testing and treatment
Antibiotic-sensitive gonorrhoea
Individuals infected with antibiotic-sensitive gonorrhoea,
ISeni , can recover spontaneously at rate ν or seek care
(Fig. 1, left). Symptomatic care-seekers receive treatment
on the same day at rate τS. Asymptomatic care-seekers,
i.e., those who are screened for gonorrhoea or were noti-
fied through an infected partner, are tested at rate τA.
Gonorrhoea is detected with sensitivity ξG. On average, a
fraction λA of asymptomatic individuals returns for treat-
ment after δ days. The treatment rate for asymptomatic
individuals is approximated by 1/(1/τA + δ), the inverse
of the average time until individuals are tested, 1/τA, and
the time until they return for treatment, δ. Both symp-
tomatic and asymptomatic individuals are treated with
a first-line antibiotic that has treatment efficacy η1. We
assumed that individuals whose treatment was ineffica-
cious remain infected and do not seek care again immedi-
ately. This assumption reflects the notion that treatment
failure of antibiotic-sensitive gonorrhoea is most likely to
occur in pharyngeal infections, which are usually asymp-
tomatic [21].
Antibiotic-resistant gonorrhoea
Individuals infected with gonorrhoea resistant to the first-
line antibiotic, IResi , can also recover spontaneously at
rate ν (Fig. 1, right). Asymptomatic care-seekers that
return for treatment (fraction λA) receive treatment with
the second-line antibiotic at rate 1/(1/τA + δ) if both
gonorrhoea (sensitivity ξG) and resistance (sensitivity ξR)
are detected. Symptomatic care-seekers receive the first-
line antibiotic as treatment on the same day, but remain
infected due to resistance and return for treatment after
δ days. At their second visit, symptomatic care-seekers
receive the second-line antibiotic if both gonorrhoea (sen-
sitivity ξG) and resistance (sensitivity ξR) are detected. If
either test fails, they do not receive the second-line antibi-
otic. If they remain symptomatic (fraction λS), they wait
for re-treatment in compartment Wi, where they either
receive re-treatment with the second-line antibiotic at rate
ω or recover spontaneously at rate ν. The assumption
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Fig. 1 Clinical pathway for the testing and treatment of gonorrhoea infections. Gonorrhoea patients can recover spontaneously or seek care for
their infection. Depending on the parameter values of δ, λA , and ξR (Table 2), patients are tested with culture, NAAT, POC − R, or POC + R when they
seek care. In the NAAT and POC − R scenarios, “Resistance detected?” (yellow) defaults to “no”. In POC − R and POC + R, “returns for treatment?”
(blue) defaults to “yes”. In the culture scenario, the flowchart is followed as shown. Dashed arrows indicate that individuals remain infected. NAAT
nucleic acid amplification test, POC point-of-care, POC + R POC test with resistance detection, POC − R POC test without resistance detection, PN
partner notification
that re-treatment occurs with the second-line antibiotic
follows recommendations from theWorld Health Organi-
zation (WHO) [20] and the Centers for Disease Control
(CDC) [22] to obtain a specimen for culture-based antibi-
otic resistance testing at a patient’s second visit. The
second-line antibiotic has efficacy η2; individuals whose
treatment is inefficacious remain infected and can recover
spontaneously or seek care at a later point. De novo
resistance to the first-line antibiotic or resistance to the
second-line antibiotic are not considered in the model.
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Table 1 Gonorrhoea testing and treatment parameters and their default values
Parameter Description (unit) Baseline Culture NAAT POC + R POC − R
τS Rate at which symptomatic individuals seek
care (y−1)
Variablea See baseline See baseline See baseline See baseline
τA Rate at which asymptomatic individuals seek
care (y−1)
Variablea See baseline See baseline See baseline See baseline
ξG Test sensitivity to detect gonorrhoea 99%b See baseline See baseline See baseline See baseline
ξR Test sensitivity to detect resistance against
the first-line antibiotic
Any value 99%c 0%d 99%c 0%d
η1, η2 Efficacy of first-line (1) or second-line (2)
antibiotic
99%e See baseline See baseline See baseline See baseline
δ Average time after test individuals return for
treatment (days)
7f See baseline See baseline 0d 0d
1/ω Average time individuals with resistant gon-
orrhoea wait for re-treatment (days)
7c See baseline See baseline See baseline See baseline
λA Fraction of asymptomatic individuals who
return for treatment
90%c See baseline See baseline 100%d 100%d
λS Fraction of symptomatic individuals who
remain symptomatic after failed treatment
90%c See baseline See baseline See baseline See baseline
ψ Fraction of successfully treated individuals
who were symptomatic at baseline
60%f – – – –
Unless a value is set by definition, all values listed are default values and are varied in sensitivity analyses. Baseline: Resistance-free scenario (corresponds to scenario where
culture or NAAT is used; ξR can take any value since there is no resistance to detect). Culture, NAAT, POC − R, or POC + R refer to scenarios after resistance is introduced
NAAT nucleic acid amplification test, POC point-of-care, POC + R POC test with resistance detection, POC − R POC test without resistance detection
aDerived
b[35]
cAssumption
dBy definition
e[23, 36]
f[11]
Testing scenarios
We simulated clinical pathways of gonorrhoea patients
who are tested with culture, NAAT, or POC test at
their first visit by adapting the parameters δ, λA, and
ξR (Table 2). For culture, test results are not available
immediately (δculture > 0), resistance can be detected
(ξR,culture > 0), and asymptomatic infected individu-
als might not return for treatment (λA,culture < 1). For
NAAT, test results are not available immediately (δNAAT >
Table 2 Culture, NAAT, and POC testing scenarios are
determined by the values of δ, λA , and ξR
Scenario δ λA ξR
Culture > 0 < 1 > 0
NAAT > 0 < 1 = 0
POC = 0 = 1 ≥0
POC + R = 0 = 1 > 0
POC − R = 0 = 1 = 0
Culture, NAAT, and POC testing scenarios can be simulated with the same
mathematical model by adapting the average time after test that individuals return
for treatment (δ), the fraction of asymptomatic individuals who return for treatment
(λA), and the test sensitivity to detect resistance against the first-line antibiotic (ξR)
NAAT nucleic acid amplification test, POC point-of-care, POC+ R POC test with
resistance detection, POC− R POC test without resistance detection
0), resistance cannot be detected (ξR,NAAT = 0), and
asymptomatic infected individuals might not return for
treatment (λA,NAAT < 1). For POC, test results are avail-
able immediately (δPOC = 0), all individuals are followed
up (λA,POC = 1), and thus all individuals are treated at
the first visit. We explore the impact of a POC test with
(ξR,POC > 0, POC + R) and without resistance detection
(ξR,POC = 0, POC−R); we use the term “POC” alone when
ξR,POC is variable.
Impact measures
We evaluated the impact of a testing scenario by cal-
culating the proportion of resistant infections among
all infections, observed cases averted, and the rate at
which resistance spreads, compared with another test-
ing scenario. We measured the proportion of resis-
tant infections up to 30 years after the introduction of
resistance into the resistance-free baseline scenario. If
applicable, we also calculated the time until resistance
levels reached 5%, the level above which an antibiotic
should not be used for empirical gonorrhoea treatment
[23]. We defined observed cases averted as the dif-
ference between the cumulative incidence of observed
cases (i.e., cases diagnosed and successfully treated at
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baseline; fraction φ [19]) using NAAT and the cumula-
tive incidence of observed cases using culture or POC
tests. We calculated the observed cases averted 5 years
after the introduction of resistance. The rate at which
resistance spreads describes how fast resistant infec-
tions replace sensitive infections in a human population
[19]. We calculated the ratio of the rate of resistance
spread between POC with different test sensitivities to
detect resistance (ξR,POC) and culture or NAAT scenar-
ios (Additional file 1: Section Rate of resistance spread).
If the ratio of the rate of resistance spread is >1, resis-
tance spreads faster when using POC tests compared
with other tests. If the ratio is <1, resistance spreads
slower when using POC tests compared with other
tests.
Parameters
We used the parameters describing sexual behaviour, gon-
orrhoea transmission, natural history, and treatment from
our previous model [19]. There, we estimated sexual
behaviour parameters from the second British National
Survey of Sexual Attitudes and Lifestyles (Natsal-2), which
is a nationally representative population-based survey
[24]. We calibrated all other parameters to yield preva-
lence and incidence rates within empirically observed
ranges (Tables 3 and 4). We assumed that the empir-
ically observed values refer to a period during which
treatment was mostly effective and thus, used model
simulations without resistance for the calibration. For
this study, we used subsets of 1000 calibrated parame-
ter sets from the previous study to simulate MSM and
HMW populations (prevalence and incidence rates in
Additional file 1: Figures S2 and S3). For each cali-
brated parameter set, we derived the care-seeking rate
of asymptomatic (τA) and symptomatic (τS) individu-
als using the fraction of successfully treated individuals
who were symptomatic at baseline φ (Additional file 1:
Section Derivation of τA and τS). We set default val-
ues for the testing and treatment parameters (ψ , ξG,
ξR, η1, η2, δ, ω, λA, and λS) guided by the literature
(Table 1).
Sensitivity Analyses
We performed sensitivity analyses to confirm that our
model results are robust in scenarios with different prop-
erties of tests (ξG and ξR), antibiotics (η1 and η2), and
populations and clinics (δ, ω, λA, and λS). First, we per-
formed sensitivity analyses of the observed cases averted
with regard to changes in both the fraction of asymp-
tomatic individuals who return for treatment at baseline
(λA,baseline) and the fraction of successfully treated indi-
viduals who were symptomatic at baseline (ψ), as well
as to changes in single testing and treatment parame-
ters (ξG, ξR, λA,baseline, λS, ψ , δbaseline, and ω). Second,
we evaluated the sensitivity of the ratio of resistance
spread with regard to changes in the test sensitivity to
detect resistance against the first-line antibiotic when
using POC (ξR,POC), the fraction of asymptomatic indi-
viduals who return for treatment at baseline (λA,baseline),
and the fraction of successfully treated individuals who
were symptomatic at baseline (ψ). Third, we tested the
sensitivity of our model results to the assumption that
the test sensitivity to detect N. gonorrhoeae is 99% for
culture testing. For this, we simulated an alternative
scenario where culture has a lower test sensitivity to
detect N. gonorrhoeae and only culture is used at baseline
(ξG,baseline = ξG,culture = 90%, all other parameters as in
Table 1).
Simulation
For each parameter set, we first simulated a resistance-
free baseline scenario where either culture or NAAT is
used (δ > 0, λA < 1). We simulated the baseline
scenario until it reached equilibrium using the func-
tion runsteady in the package rootSolve [25] from
the R language and software environment for statistical
computing [26]. Next, we introduced resistant strains by
converting 0.1% of all sensitive infections into resistant
infections. We then set the parameter ξR to reflect the
different testing scenarios (culture, NAAT, POC + R, or
POC − R). For POC tests, we additionally set δ = 0 and
λA = 1. Finally, we simulated themodel using the function
lsoda from the R package deSolve [27].
Table 3 Gonorrhoea prevalence and incidence in baseline scenario (before resistance introduced) for men who have sex with men
Range used for calibration Baseline median (IQR)
Prevalence low activity class (%) 0–2.79 0.59 (0.42–0.79)
Prevalence high activity class (%) 1.19–100 27.64 (23.25–31.91)
Prevalence total population (%) 1.19–2.79 2.09 (1.69–2.43)
Incidence total population (100 000 persons−1 y−1) 5880–7190 6493.49 (6192.89–6842.70)
The prevalence and incidence ranges used for calibration for men who have sex with men were based on the Health in Men Study in Australia [37]. The baseline median and
IQR are based on the simulation results of 1000 calibrated parameter sets. The upper and lower bounds of the calibration range for the low and high sexual activity classes
were set to the lower and upper bounds for the total population. The calibration is detailed in [19]
IQR interquartile range
Fingerhuth et al. BMCMedicine  (2017) 15:142 Page 6 of 12
Table 4 Gonorrhoea prevalence and incidence in baseline scenario (before resistance introduced) for heterosexual men and women
Range used for calibration Baseline median (IQR)
Prevalence low activity class (%) 0–0.38 0.12 (0.09–0.15)
Prevalence high activity class (%) 0.16–100 2.14 (1.71–2.60)
Prevalence total population (%) 0.16–0.38 0.25 (0.21–0.3)
Incidence total population (100 000 persons−1 y−1) 120–360 222.13 (172.19–283.54)
The prevalence and incidence ranges used for calibration for heterosexual men and women were based on the National Health and Nutrition Examination Survey [38] and
surveillance data [39], both from CDC. The baseline median and IQR are based on the simulation results of 1000 calibrated parameter sets. The upper and lower bounds of the
calibration range for the low and high sexual activity classes were set to the lower and upper bounds for the total population. The calibration is detailed in [19]
CDC Centers for Disease Control, IQR interquartile range
Results
Proportion of resistant infections
We determined the proportion of gonorrhoea infections
resistant to the first-line antibiotic for up to 30 years after
the introduction of resistance (Fig. 2). The proportion
of resistant infections remains lowest when POC + R is
used (MSM: median 0.18% after 30 years, interquartile
range (IQR) 0.17–0.21%; HMW: 0.12%, 0.11–0.12%). The
proportion of resistant infections also remains low with
culture (MSM: 1.19%, 0.68–3.59%, HMW: 0.13%, 0.12–
0.15%). In contrast, resistant infections largely replace
sensitive infections after 30 years using NAAT (MSM:
100%, 100–100%, HMW: 99.27%, 88.54–99.97%) and
POC−R (MSM: 100%, 100–100%, HMW: 99.73%, 94.30–
99.99%). The proportion of resistant infections exceeds
the 5% resistance threshold (Fig. 2, dashed line) marginally
Fig. 2 Time line of the proportion of resistant gonorrhoea infections when using culture, NAAT, POC − R, or POC + R. The proportion of resistant
infections remains lowest when POC + R is used, followed by culture. The proportion of resistant infections exceeds the 5% threshold (dashed lines)
marginally earlier with POC − R than with NAAT. The continuous lines give the median proportion of resistant infections over all simulations. Shaded
areas indicate that 50% or 95% of all simulations lie within this range. HMW heterosexual men and women,MSMmen who have sex with men, NAAT
nucleic acid amplification test, POC point-of-care, POC+ R POC test with resistance detection, POC− R POC test without resistance detection
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earlier when POC − R is used (MSM: median <2.42,
IQR 2.00–2.92 years, HMW: <9.25, 7.25–12.25 years)
than when NAAT is used (MSM: <2.58, 2.08–3.08 years,
HMW: <10.08, 7.83 − 13.33 years). Overall, POC + R
performs best in keeping the proportion of resistant infec-
tions low and POC − R performs worst.
We tested the sensitivity of the proportion of resis-
tant infections to the assumption that the test sensitiv-
ity to detect N. gonorrhoeae is 99% for culture testing
(ξG,culture = 99%) by simulating an alternative scenario
where culture has a lower test sensitivity to detect N.
gonorrhoeae and only culture is used at baseline (with
ξG,baseline = ξG,culture = 90% and all other values as
in Table 1; Additional file 1: Figure S12). The propor-
tions of resistant infections after 30 years are higher when
ξG,baseline = ξG,culture = 90% for the culture scenario
(MSM: median 3.18%, IQR 1.51–11.33%; HMW: 0.16%,
0.14–0.20%) and slightly higher for the other tests (NAAT
MSM: 100%, 100–100%, HMW: 99.71%, 94.04–99.99%;
POC − R MSM: 100%, 100–100%, HMW: 99.91%, 97.38–
100.00%; POC + R MSM: 0.19%, 0.17–0.22%, HMW:
0.12%, 0.11–0.12%). The proportion of resistant infections
exceeds 5% slightly earlier when ξG,baseline = ξG,culture =
90% in the POC−R scenario (MSM: median <2.25 years,
IQR 1.83–2.67 years, HMW: <8.58 years, 6.75–11.33
years) and NAAT scenario (MSM: <2.42 years, 2.00–2.83
years, HMW: 9.33 years, 7.25–12.33 years).
Observed cases averted
We calculated the observed cases averted (per 100 000
persons) after 5 years using culture, POC+R, or POC−R
in comparison with NAAT (Fig. 3). For the default values
(λA,baseline = 90% and ψ = 60%), using NAAT leads to
a median of 36 366 (IQR 33 789–39 692) observed cases
after 5 years for MSM and 1228 (927–1610) for HMW.
Culture averts 1876 (740–4919) cases in MSM and 3 (1–
7) in HMW compared with NAAT. POC + R averts even
more cases than culture in both MSM (3353, 1697–7259)
andHMW (118, 69–198). POC−R averts fewer cases than
culture in MSM (772, 452–1119), but about the same as
POC + R in HMW (115, 68–190).
First, we performed sensitivity analyses of the observed
cases averted with regard to changes in both the fraction
of asymptomatic individuals who return for treatment
at baseline (λA,baseline) and the fraction of successfully
treated individuals who were symptomatic at baseline (ψ)
(Fig. 3). For culture, increasing the fraction of asymp-
tomatic individuals who return for treatment at baseline
(λA,baseline) and decreasing the fraction of successfully
treated individuals who were symptomatic at baseline (ψ)
increases the median observed cases averted. For POC +
R, decreasing λA,baseline and decreasing ψ leads to an
increase in the median observed cases averted. For POC−
R, a decreasing value of λA,baseline and an intermediate
value of ψ results in an increase in median averted cases.
Fig. 3 Two-dimensional sensitivity analysis of observed cases averted (per 100 000 persons) after 5 years. The sensitivity analysis is performed with
respect to the fraction of asymptomatic individuals who return for treatment at baseline (λA,baseline) and the fraction of successfully treated individuals
who were symptomatic at baseline (ψ ), for aMSM and b HMW. The central right plot of each panel shows the default scenario (λA,baseline = 90%
and ψ = 60%). Lower and upper bounds in a box indicate the first and third quartiles. The bar in a box indicates the median and the whiskers span
1.5 times the interquartile range. Outliers are not shown for clarity. HMW heterosexual men and women,MSMmen who have sex with men, NAAT
nucleic acid amplification test, POC point-of-care, POC+ R POC test with resistance detection, POC− R POC test without resistance detection
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For all combinations of λA,baseline and ψ in both MSM and
HMW, POC + R averts more cases at the median than
culture.
Second, we performed sensitivity analyses of the
observed cases averted with regard to changes in sin-
gle testing and treatment parameters. Decreasing the test
sensitivity to detect resistance against the first-line antibi-
otic (ξR,POC or ξR,culture, Additional file 1: Figure S6),
the average time after test individuals return for treat-
ment (δbaseline, Additional file 1: Figure S10) or the aver-
age time individuals with resistant gonorrhoea wait for
re-treatment (1/ω, Additional file 1: Figure S11) leads
to a decrease in the median observed cases averted in
POC + R and culture for both MSM and HMW. Decreas-
ing the fraction of symptomatic individuals who remain
symptomatic after failed treatment (λS, Additional file 1:
Figure S8) or the fraction of successfully treated individ-
uals who were symptomatic at baseline (ψ , Additional
file 1: Figure S9) leads to an increase in the median
observed cases averted when using POC + R and culture
for both MSM and HMW. Decreasing the test sensitiv-
ity to detect gonorrhoea (ξG, Additional file 1: Figure S5)
or the fraction of asymptomatic individuals who return
for treatment at baseline (λA,baseline, Additional file 1:
Figure S7) leads to an increase in the median observed
cases averted when using POC + R, but to a decrease
in the median observed cases averted when using cul-
ture. For the same parameter values, POC + R averts
more cases at the median than culture in both MSM
and HMW.
Third, we simulated an alternative scenario where cul-
ture has a lower test sensitivity to detect N. gonor-
rhoeae and only culture is used at baseline (ξG,baseline =
ξG,culture = 90% and all other values as in Table 1;
Additional file 1: Figure S13). In the alternative scenario,
the number of observed cases averted after 5 years using
POC + R compared with NAAT is larger than in the
default scenario for MSM (median 4236, IQR 2161–8839
per 100 000 persons). The observed cases averted after
5 years compared with NAAT are similar to the default
scenario when using POC + R for HMW (119, 72–195),
POC − R for MSM (800, 452–1173) and HMW (116,
70–188), and culture for MSM (1863, 733–4908) and
HMW (3, 1–7).
Ratio of resistance spread
We determined the ratio of the rate of resistance spread
between POC and culture (Fig. 4) and POC and NAAT
(Fig. 5). For the default values (ξR,culture = 99%, ξR,NAAT =
0%, ξR,POC = 99%, λA,baseline = 90%, and ψ = 60%),
resistance spreads more slowly with POC compared with
culture or NAAT.
First, we tested the sensitivity of the ratio of resistance
spread to changes in the test sensitivity of POC to detect
resistance (ξR,POC). Decreasing ξR,POC can result in a faster
spread of resistance with POC. A slight decrease in ξR,POC
to 80–95% leads to faster resistance spread with POC
compared with culture (Fig. 4). In contrast, only very low
values of ξR,POC result in a faster resistance spread for
POC compared with NAAT (Fig. 5).
Second, we tested the sensitivity of the ratio of resis-
tance spread to changes in the fraction of asymp-
tomatic individuals who return for treatment at baseline
(λA,baseline) and the fraction of successfully treated indi-
viduals who were symptomatic at baseline (ψ). Increas-
ing λA,baseline leads to a lower ratio of resistance spread
between POC and culture (Fig. 4) and POC and NAAT
(Fig. 5). Similarly, increasing ψ leads to a lower ratio of
resistance spread between POC and culture (Fig. 4) and
POC and NAAT (Fig. 5).
Third, we simulated an alternative scenario where cul-
ture has a lower test sensitivity to detect N. gonor-
rhoeae and only culture is used at baseline (ξG,baseline =
ξG,culture = 90% and all other values as in Table 1;
Additional file 1: Figure S14). If the ratio of resistance
spread between POC and culture is above 1 in the default
scenario, the ratio of resistance spread between POC and
culture is smaller with the alternative scenario than with
the default scenario. In contrast, if the ratio of resistance
spread between POC and culture is below 1 with the
default scenario, the ratio of resistance spread between
POC and culture is larger with the alternative scenario
than with the default scenario. The ratio of resistance
spread between POC and NAAT is less affected by a
different value of ξG,baseline.
Discussion
Using a mathematical transmission model, we compared
the expected impact of POC tests on gonorrhoea cases
and antibiotic resistance with conventional tests, cul-
ture and NAAT. We found that POC tests that detect
antibiotic resistance with a sensitivity of 99% avert more
gonorrhoea cases than any other test across all simu-
lated settings. Additionally, we found that POC tests can
slow down the spread of resistance if their test sensi-
tivity to detect resistance is sufficiently high. If the test
sensitivity of a POC test to detect resistance is higher
than 0–40%, resistance spreads more slowly than with
NAAT, and if POC sensitivity to detect resistance is higher
than 80–95%, resistance spreads more slowly than with
culture.
We captured the basic principles of the gonorrhoea test-
ing and treatment process for culture, NAAT, and POC in
a single model structure. The parameters describing the
sexual behaviour and the natural history of gonorrhoea
were estimated and calibrated in a previous study [19].
The default parameters that describe testing and treat-
ment of gonorrhoea were based on literature values and
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Fig. 4 Three-dimensional sensitivity analysis of the ratio of resistance spread between POC and culture. Shown are the ratios of resistance spread for
MSM and HMW for ξR,culture = 99% and different values of ξR,POC, λA,baseline, and ψ (POC − R: ξR,POC = 0, POC + R: ξR,POC > 0). The shaded areas
indicate that resistance spread is slower when using POC than when using culture. For the default values (ξR,POC = 99%, λA,baseline = 90%, and
ψ = 60%), resistance spread is slower when using POC than when using culture. For most other values shown, using POC accelerates resistance
spread. Each data point gives the median value over 1000 simulations (one per calibrated parameter set). Some calibrated parameter sets lead to
the extinction of gonorrhoea in the simulation (Additional file 1: Figure S4). In these simulations, resistance did not spread and the ratio of resistance
spread could not be calculated. Data points for these simulations were excluded from this figure since they would show the median ratio of
resistance spread over less than 1000 simulations. Note that the y-axis is shown in logarithmic scale. HMW heterosexual men and women,MSMmen
who have sex with men, POC point-of-care, POC+ R POC test with resistance detection, POC− R POC test without resistance detection
are measurable. The model results are robust in sensitiv-
ity analyses (Figs. 3, 4 and 5, Additional file 1: Figures
S5–S14). Themodel can be used to help design trials com-
paring different test strategies and guide the introduction
of POC tests in the future.
Mathematical models generally depend on assumptions
that should be taken into consideration when interpreting
model results. We managed the complexity of our model
with the following assumptions.
First, we did not consider test specificity. A low test
specificity to detect resistance against the first-line antibi-
otic would result in increased use of the second-line
antibiotic, and thus, simultaneously decrease the level
of resistance against the first-line antibiotic and increase
the level of resistance against the second-line antibiotic.
Since we focused on resistance against the first-line antibi-
otic, we could not capture the impact of test specificity
appropriately.
Second, our model does not include a change in antibi-
otic recommendations: undetected resistant infections
are always treated with the first-line antibiotic, even if
all infections in the population are resistant. This clin-
ical pathway increases the average duration of resis-
tant infections and possibly the observed cases. Whilst
this is unlikely in high-income countries with good
antibiotic resistance surveillance, it is not an unrealis-
tic scenario in resource-poor settings without surveil-
lance where 71–100% of gonococcal strains are resis-
tant to fluoroquinolones [28]. In our model, MSM have
a substantial level of resistant gonorrhoea infections
after 5 years using NAAT. We expect that our model
overestimates the observed cases using NAAT and the
observed cases averted using culture and POC + R com-
pared with a model including a change in antibiotic
recommendations.
Third, we considered treatment with a single antibiotic
although current treatment guidelines recommend a com-
bination therapy with two antibiotics simultaneously [1,
7]. Themodel results are fully applicable to treatment with
combination therapy if antibiotic-resistant gonorrhoea is
interpreted as resistance against both antibiotics used for
combination therapy.
Fourth, we investigated the effects of one test at a time
and did not consider the effects of mixed testing. Our
results, therefore, show only what the ideal effects of each
test could be.
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Fig. 5 Three-dimensional sensitivity analysis of the ratio of resistance spread between POC and NAAT. Shown are the ratios of resistance spread for
MSM and HMW for ξR,NAAT = 0% and different values of ξR,POC, λA,baseline, and ψ (POC − R: ξR,POC = 0, POC + R: ξR,POC > 0). The shaded areas
indicate that resistance spread is slower when using POC than when using NAAT. For the default values (ξR,POC = 99%, λA,baseline = 90%, and
ψ = 60%) and most other values shown, resistance spread is slower when using POC than when using NAAT. Each data point gives the median
value over 1000 simulations (one per calibrated parameter set). Some calibrated parameter sets lead to the extinction of gonorrhoea in the
simulation (Additional file 1: Figure S4). In these simulations, resistance did not spread and the ratio of resistance spread could not be calculated.
Data points for these simulations were excluded from this figure since they would show the median ratio of resistance spread over less than 1000
simulations. HMW heterosexual men and women,MSMmen who have sex with men, NAAT nucleic acid amplification test, POC point-of-care, POC
+ R POC test with resistance detection, POC− R POC test without resistance detection
Fifth, we simplified the testing and treatment process.
To compare the testing scenarios better, we did not model
care-seeking and returning for treatment as separate pro-
cesses, but approximated the overall treatment rates. In
accordance with WHO [20] and CDC recommendations
[22], we assumed that re-treatment of resistant infections
occurs with the second-line antibiotic because a resistance
profile has been determined after the second visit.
Sixth, for better comparability we assumed that culture,
NAAT, and POC tests have the same sensitivity to detect
gonorrhoea, even though culture has a lower sensitivity
to detect rectal or pharyngeal gonorrhoea than molecu-
lar tests [29]. Our sensitivity analysis showed that a lower
culture test sensitivity to detect gonorrhoea of 90% had a
small effect on the model results.
Finally, it should be mentioned that the minimal POC
test sensitivity to detect resistance that is necessary to
slow down resistance spread will depend on the tests cur-
rently used, the setting, and population, and should be
subject to validation.
Currently, there are no commercial POC tests that can
detect antibiotic-resistant N. gonorrhoeae [12] and there
remain challenges for their development. First, molec-
ular POC test that detect resistance need molecular
markers that reliably predict phenotypic resistance. So far
only markers that predict resistance against some antibi-
otics are known [12, 30, 31]. Second, diagnostic tests
need to deliver results fast to be considered POC. The
fastest molecular diagnostic test for gonorrhoea that is
commercially available takes 90 minutes [9, 32], which
might be too long to wait for some patients. Finally,
costs and training requirements for molecular tests have
hindered their availability in low-income countries so
far [33].
This study addresses two key questions for gonor-
rhoea control and resistance [34]. First, we investigated
the potential impact of a POC test that detects antibi-
otic resistance (POC + R). We found that POC + R
can slow resistance spread and reduce the number of
gonorrhoea cases compared with culture or NAAT. The
impact of POC + R is particularly strong when the frac-
tion of asymptomatic individuals who return for treat-
ment (λA,baseline) and the fraction of successfully treated
individuals who were symptomatic (ψ) were low before
POC + R is introduced. However, when the POC test
cannot detect resistance (POC − R), the benefits of
POC are outweighed by accelerated resistance evolution.
Because fewer patients are lost to follow-up, more patients
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are treated and more antibiotic treatment selects more
strongly for antibiotic resistance. Since resistance cannot
be detected, resistance levels increase and fewer cases are
averted.
Second, we investigated the impact of POC tests in two
populations with different levels of risk of gonorrhoea,
MSM and HMW. We found that in both populations,
POC tests with reliable resistance detection (POC + R)
slow down the spread of resistance and avert the highest
number of cases. POC tests without resistance detection
(POC−R) avert about as many cases as POC+R in HMW,
but clearly fewer cases than POC+R inMSM. Since resis-
tance usually spreads faster inMSM [19], the faster spread
of resistance caused by POC−R impacts the cases averted
after 5 years in MSM, but not in HMW. POC tests that
detect resistance reliably are crucial for both populations
and both populations need culture-based surveillance of
resistance to keep molecular markers for POC resistance
detection updated.
Conclusions
This modelling study addresses clinically relevant situa-
tions to evaluate the potential impact of gonorrhoea POC
tests on antibiotic-resistant gonorrhoea and can guide the
introduction of POC tests. POC tests with high sensitivity
to detect resistance may replace culture-based diagnosis
in clinical settings, as long as culture-based surveillance
of antibiotic resistance is maintained to monitor resis-
tance levels and to determine molecular markers for POC
tests. POC tests with lower sensitivities to detect resis-
tance should not replace culture-based diagnosis, but
might have some advantages over NAAT. POC tests with
low or no sensitivity to detect resistance should not be
introduced, because POC tests without reliable resistance
detection can accelerate the spread of antibiotic-resistant
gonorrhoea.
Additional file
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model, figure showing fraction of simulations in which gonorrhoea was
eradicated, figures showing sensitivity analyses. (PDF 488 kb)
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